QL9

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

QL9 is derived from the enzyme 2-oxoglutarate dehydrogenase and belongs to the endogenous peptide repertoire of all H-2d APCs.

QL9 is derived from the enzyme 2-oxoglutarate dehydrogenase and belongs to the endogenous peptide repertoire of all H-2d APCs.(In Vitro):Mouse T cell clone 2C recognizes two different major histocompatibility (MHC) ligands, the self MHC Kb and the allogeneic MHC Ld. Two distinct peptides, SIY (SIYRYYGL) and QL9 (QLSPFPFDL), act as strong and specific agonists when bind to Kb and Ld, respectively. QL9 binding to MHC Ld is influenced by the majority of peptide side chains, distributed across the entire length of the peptide. Findings with both systems, but QL9-Ld in particular, suggest that many single-residue substitutions, introduced into peptides to improve their binding to MHC and thus their vaccine potential, could impair T cell reactivity due to their dual impact on TCR binding. T cell activation assays are performed to measure effects of peptide SIY and QL9 residues on T cell function.

——

Others

Other Targets

TCR

——

——

159646-83-0

1063.2

C52H74N10O14

>98% (HPLC)

H2O : 33.33 mg/mL (31.35 mM; Need ultrasonic)

——

Sequence:Gln-Leu-Ser-Pro-Phe-Pro-Phe-Asp-Leu

(-20℃)

With Ice Pack

≥ 2 years